FDA Lifts Clinical Hold on Intellia's MAGNITUDE Gene Therapy Trial

Key Facts

The U.S. Food and Drug Administration (FDA) has officially removed the clinical hold on Intellia Therapeutics' Phase 3 clinical trial, known as MAGNITUDE, for its experimental gene therapy. This decision allows the company to proceed with late-stage testing of the treatment, which targets a specific form of heart disease. The lifting of the hold indicates that Intellia has successfully addressed previous regulatory or safety concerns raised by the agency. Shares of Intellia Therapeutics (NTLA) rose on Monday following the announcement, as investors reacted positively to the reduction in regulatory risk. This development marks a significant milestone for the biotech firm, clearing a major hurdle toward potential commercialization. The resumption of the MAGNITUDE trial reinforces market confidence in Intellia's gene-editing pipeline for chronic diseases.